The natural history of chronic diseases is generally poorly understood. Multiple sclerosis is one of the beststudied diseases and we outline here some of the information obtained from 25 000 patient-years of observation. This population-based cohort received almost no treatment and certainly none known to alter the long-term natural course of the illness. There is a possibility that such data will prove useful in new generation clinical trials which are observational in nature.
Introduction
As we have reached the new millennium and the extraordinary power of the scientific method is being employed to solve the remaining intractable problems, it is sobering to realise that the natural history of most chronic diseases is incompletely if not poorly understood. Even in the year 2000, there is a large price to pay for unfamiliarity with the natural history of disease. MS is no exception.
Fever represents an interesting paradigm both from the standpoint of classification of disease -it is obviously not a disease -and from the standpoint of treatment. There was a time when fever was considered to be a disorder unto itself. The ancients believed it secondary to too much blood -a Galaenic notion that proved to be surprisingly durable. Blood letting ceased in the Western world only after the turn of the last century and if one examines the logic behind it, it becomes much more understandable. If fever were due to too much blood as "confirmed" by a strong bounding pulse, the removal of blood being found to diminish the pulse made sense. Indeed the hypothesis was seemingly confirmed by the fact that blood letting led to improvement in most fevers. What was not well understood was the natural history of fevers which we now know to be benign in most cases. It could be argued then that ignorance of the natural history of a disorder has been responsible for most of the type 1 errors made by physicians over the ages.
It can be argued now in the year 2000 that clinical trials continue to be done to evaluate the effects of therapy because the outcome in a control group cannot be predicted reliably particularly in the short term. The ideal natural history study would entail identification of an inception cohort. This would be a group of patients with the disease who are population-based, so that selection bias associated with poor outcome, common to hospital-and clinic-based series, could be avoided. The patients should ideally be seen at the onset of the disease and followed through to the end and there should be no dropouts nor cases misdiagnosed or escaping ascertainment. In practice this is impossible to achieve for many reasons. Those particular to MS relate to the long duration of the disease, the existence of sub-clinical forms, and the fact that some patients never see physicians even though they have prominent symptoms. The rate of misdiagnosis has probably been low in established centres for some decades now. But even in the best of hands, 5% of patients thought to have MS will not be confirmed at autopsy. For practical purposes this is an acceptable rate of accuracy. Perhaps the most elusive target would be to find a cohort of patients who have received no treatment. The best that can be hoped for in the Western world would be a group receiving no treatment that might affect outcome. Fortunately in MS this has been easy since no therapy has been shown to affect the long-term course of the illness. [1] The London MS Clinic
This Clinic was begun in 1972 by Don Paty and by 1977 when I arrived there were some 400 patients. When I left London in 1999 this number had grown to 4500. The original cohort collected for a study of natural history ended accrual in 1984 and included 1099 patients. This cohort received very little treatment except for steroids at the times of acute exacerbations, and initial findings were published in a series of papers in Brain between 1989 and 1991 [2] [3] [4] [5] .
The findings of the original study as they relate to the early course of MS were that there is an association between frequent early relapses and outcome. This held true after multivariate analysis. The empirical survival curves were calculated for the total population, the restricted and epidemiologically valid Middlesex County cohort, the cohort of patients having attack onset and those with primary progressive disease.
Primary progressive patients constituted nearly 20% of the total population being defined as one year gradual progression in the absence of exacerbation. The cohort was followed up over the last two years such that this database now constitutes some 25 000 patient-years of control information. The follow-up exceeded 95% with the aid of a concerted effort to keep track of patients, government registries for death and because of extraordinary cooperation on the part of the patient cohort themselves. It is possible that such a study can no longer be repeated because of the prevalence of treatment, the increased mobility of populations, and not least investigator fatigue.
The longer follow-up at 25 years has now ensured that most patients have reached hard outcome measures with more than one-third having died, and another third having reached or exceeded DSS6. We were able to completely evaluate all prognostic parameters, following the exclusion of (1) a small number of patients shown not to have MS, (2) the elimination of a few duplicates because of name changes, and (3) the exclusion of "possible cases". The next four papers in this series have been published [6] [7] [8] [9] . The first of these examined the natural course of primary progressive MS in a cohort of over 200 patients from the original dataset. It was readily established that this group deteriorated at a more rapid rate than patients with attack onset if onset of symptoms was chosen as the starting point. Prognostic features in primary progressive MS were identified and the relative increase in males in this population was confirmed.
With long-term, follow-up it was possible to show that nearly 30% of patients with primary progressive MS have relapses at some point, often many years into the course of the illness. However it was shown that the presence of relapses in such cases had no bearing on outcome since those with no relapses did just as well as those with relapses. These findings give no support to the existence of "progressive relapsing MS" as a separate entity.
The median times to disability were calculated for relapsing-remitting and primary progressive MS (Table 1 ). These showed a median time of 15 years to EDSS 6, 20 years for EDSS 7 and 25 years for EDSS 8 in the relapsing-remitting group. In the primary progressive group it was eight years to EDSS 6, 12 years to EDSS 7 and 15 years to EDSS 8.
The largest single predictor of outcome was the development of a progressive course followed by the relapse rate in the first two years. Similarly modest influences of the first inter-attack interval, polysymptomatic onset and time early disability were found.
In 681 population-based patients with relapsing-remitting disease, some 60% had one attack in the first two years while 20% had three or more.
The number of attacks in the first years had striking predictive ability when median times to EDSS 6 were examined. Patients having one attack in the first two years had a median time of 20 years to requirement of a cane while in those with five or more attacks, this duration was reduced to seven years. An effect was even demonstrable for time to EDSS 10 (death).
These findings require some interpretation. It is very tempting to assume that the number of relapses in the first two years is not only predictive but an indicator that suppressing such relapses would translate into longer times to sustained disability. This remains to be proven and it could also be argued that the association between frequent early relapses and subsequent disability is more associatative than causal. One question which came up as part of the natural history studies has been to examine the question of primary progressive multiple sclerosis. Much has been made of this as a discrete entity of some kind but this finds little support in our natural history studies. The findings indicate that primary progressive MS is rather more like attack onset MS in most regards with the relapsing course simply being removed or unidentified.
An important issue in such comparisons relates to the timing of onset of progression. Much confusion has originated from the inability to detect the onset of progression in patients who are having frequent relapses. In our view, however, it is most likely that all patients begin progressing at the same place, could it only be measured i.e. EDSS 1.
The track record of clinical trials in multiple sclerosis has not been good. The frequency of type 1 errors has been high despite numerous claims that individual studies adhere to the principles entailed by randomisation, blinding and appropriate placebo controls. Indeed it is clear that observational studies warrant re-evaluation, particularly for chronic and variable diseases like multiple sclerosis. Investigators with the very best of intentions seem largely unable to execute intact studies beyond two to three years. In this context, "intact" means a less than 15% dropout rate so that data in the end are interpretable. If we had highly effective therapies there would be no problem. The difficulty is more than that of having therapies limited to modest efficacy. Outcome measures with face validity are simply not reached within the confines of feasible clinical trials in MS when placebo controls, blinding and randomisation are demanded.
It has often been mysterious for those outside the field to understand the problems faced by investigators studying a disease of some 30-40 years duration. The application of placebo-controlled, randomised clinical trials has had excellent success in disorders characterised by counting of the events in the at-risk well (such as transient ischaemic attacks) or in diseases like cancer where the outcomes are binary and occur in relatively short order. Clinical trials in MS seem unable to reach hard outcome measures without substantial problems in the areas of blinding and dropouts. The original betaseron study is an excellent case in point. Many relapsing patients wished to discontinue their participation in the study for completely understandable and predictable reasons. They wished to get pregnant, to try alternate therapies as they thought they were doing poorly, they were tired of the necessity of self-injection, and some had enduring adverse events that were medication-related.
The existence of carefully collected and comprehensive natural history data should be viewed as providing a possible alternative to randomised placebo controls given the continuing difficulties in executing clinical trials in multiple sclerosis. These difficulties have not been in any way made less with the widespread adoption of what has been called "disease modifying drugs" in North America. There are some 110 000 patients on these therapies, but yet it is still unknown if they have any influence on the long-term course of the illness. This is frustrating since it is now 10 years since the first interferon study began.
In summary, natural history studies are extremely important to provide a basis for a nosologic classification, for apparent determination of long-term outcomes, and for giving practical advice to patients concerned about their prognosis. However, in addition to this they do have some potential use in a different paradigm of effectiveness determination. The next several years will see increasing efforts to evaluate the use of such controls in observational studies. It is hoped this will make a contribution to finding effective treatments for MS.
